Predictive Oncology Inc.
POAI
$1.06
-$0.03-2.75%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 76.92% | 24.04% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 76.92% | 24.04% | |||
| Cost of Revenue | 47.59% | 28.69% | |||
| Gross Profit | 115.73% | 18.28% | |||
| SG&A Expenses | -0.73% | -25.71% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 2.84% | -23.31% | |||
| Operating Income | 8.23% | 27.44% | |||
| Income Before Tax | 7.99% | 28.22% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 7.99% | 28.22% | |||
| Earnings from Discontinued Operations | 91.53% | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 29.89% | 2.72% | |||
| EBIT | 8.23% | 27.44% | |||
| EBITDA | 8.34% | 24.85% | |||
| EPS Basic | 32.82% | 29.06% | |||
| Normalized Basic EPS | 11.88% | 47.65% | |||
| EPS Diluted | 32.82% | 29.06% | |||
| Normalized Diluted EPS | 11.88% | 47.65% | |||
| Average Basic Shares Outstanding | 4.37% | 37.12% | |||
| Average Diluted Shares Outstanding | 4.37% | 37.12% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||